Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. - Wikidata - awgldk - TriplyDB

Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.

Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.

http://www.wikidata.org/entity/Q34607155

about

Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: a case report and literature review.5-ASA Dose-Response: Maximizing Efficacy and Adherence.Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease.Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: a first "real-life" experience in primary gastroenterology centers in Italy.Current Research in Crohn's Disease and Ulcerative Colitis: Highlights from the 2010 ACG Meeting Update on the management of inflammatory bowel disease: specific role of adalimumab.Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.Crucial steps in the natural history of inflammatory bowel disease.Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years.Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis.Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study.Advances in the management of inflammatory bowel disease.Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel disease Adalimumab in ulcerative colitis: hypes and hopes.Update on the management of ulcerative colitis.Recent advances in understanding ulcerative colitis.Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics.Mucosal healing with anti-TNF antibodies.Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.Biological therapy for ulcerative colitis.Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease.Optimizing pharmacologic management of inflammatory bowel disease.Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease.Maintenance therapy options for ulcerative colitis.Adalimumab in ulcerative colitis - efficacy, safety and optimization in the era of treat-to target.The economics of adalimumab for ulcerative colitis.Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus.The Evolving Evidence for Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Bowel Disease.Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab.Short-term effect and adverse events of adalimumab versus placebo in inducing remission for moderate-to-severe ulcerative colitis: a meta-analysis.ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY.The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions.Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis.Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study.

P2860

Q26862821-C2D883BD-DA7F-4966-A279-1E6DA22FCC40 Q26999078-8EA7C96F-ED29-4932-AFC3-B7649A008958 Q28070298-DAC5A973-5B51-4CF1-8D7C-3C620CB50A14 Q33626895-AEC03EB3-A382-4465-8475-5B7E96C53F75 Q33916329-A9F1603E-6280-4619-B294-04D054DD28A5 Q34127277-42B7D9CC-F19C-4A7F-8F0D-0198E271AA3B Q34303155-63488DDB-0998-4A99-99EF-9613E5AD674D Q34551302-9E38D4BC-0779-4F99-A2D2-739088DA989A Q35186975-EA790070-DD2A-4610-890F-BEB1B5300221 Q35188609-C0497049-79D5-4F72-A2C0-96B67A66B5B6 Q36144457-058D2090-8053-44CC-810C-5BE513842A7C Q37304268-F6D9D85D-915E-4550-BAE2-62485DFB5E9E Q37342575-4CE6C05F-D6B8-473F-80B6-F299FB61C158 Q37600224-B20A7FDA-95B1-4049-AA76-EA386C4077F0 Q37670984-A85B80ED-9FC1-4FD8-A58A-0235217E2653 Q37719806-5090EE63-AE25-4660-8698-A932712FF1C4 Q37816445-959087C5-4B91-43AE-A520-E7E27E04CE07 Q37905652-B8547B7F-B9E3-4E53-A1F8-69FEE1F250CF Q37954101-1D94F29D-DF35-48DE-A210-C2C69A60B258 Q37973313-DB21C116-B740-488F-814B-9CA46F77A58E Q38050881-CCF29F1C-CC71-44A8-BCB5-C6677A3953FC Q38102982-0362C015-93FD-42B3-8202-A0E66923E688 Q38207759-1895CAC1-7AED-474C-9398-58C1764BA389 Q38262662-688D5BD9-8507-40AE-979D-B314DCD042D7 Q38344622-F7AAE715-E30E-4671-90CC-F4CF446BD44C Q38549995-82531D30-7A4E-429B-A17B-0717287B6258 Q38687407-99C6BBBA-2AC4-4F1A-9796-3E26C51AFBA6 Q38797791-883567D3-7D26-4C91-97FA-FF00A117F20D Q38848140-C3911405-FA1C-4F49-8BA5-5490ABB58AA1 Q38895960-8F6AAF54-D7A2-48EA-BCD5-64D3CA2AB112 Q39024280-9E8E7F34-676B-4166-8808-76C24A108E81 Q39098635-E7BDA8A3-94D6-48FE-B953-4DC457DB0BE7 Q39233355-7E004617-7A90-4264-B859-4AD9DBD78EFF Q39306418-CB682CB0-858B-4DF8-AC9C-1FEEB99BD486 Q40556801-C456A496-7516-403B-83B1-DB424337A161 Q41807889-E98ABA51-B09A-4722-8C14-D61E25A261C5 Q47700572-03805280-80E3-45C8-B842-5BD3C6C3DFDE Q48059378-E9CC1E40-D4BD-4BCC-8470-CA5B2FEF019F Q49596689-D85C7520-51C9-4C9D-AACD-D9854AC5A6B8 Q50566304-6A41A999-9DD3-4AE4-A315-7800489B9BEB

P2860

Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.

http://www.wikidata.org/entity/Q34607155

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Open-label study of adalimumab ...... or intolerance to infliximab.

@ast

Open-label study of adalimumab ...... or intolerance to infliximab.

@en

Open-label study of adalimumab ...... or intolerance to infliximab.

@nl

type

label

Open-label study of adalimumab ...... or intolerance to infliximab.

@ast

Open-label study of adalimumab ...... or intolerance to infliximab.

@en

Open-label study of adalimumab ...... or intolerance to infliximab.

@nl

prefLabel

Open-label study of adalimumab ...... or intolerance to infliximab.

@ast

Open-label study of adalimumab ...... or intolerance to infliximab.

@en

Open-label study of adalimumab ...... or intolerance to infliximab.

@nl

P1433

Q34607155-C87934F0-2940-461E-8780-82C9BCA73C18

P1476

Q34607155-564260F9-BDF9-444F-A73E-E0571A553E5E

P2093

Q34607155-22A9E1CD-1E81-4061-A31C-D2CD1F3C6639

Q34607155-50A9543F-91E2-4121-82F3-26374F63E480

Q34607155-5F19A51D-0E4C-4C5F-ACFA-35157092D81C

Q34607155-679AAB39-8125-42D1-8ABC-DF9636E06E16

Q34607155-7D11E705-2C1A-4A72-9D98-3123D52A3D2E

Q34607155-89A90CAC-6CA2-4F43-BB6D-6279DC2B810C

Q34607155-8B332E4F-BCD4-47F8-9747-DBB0511EC8FA

Q34607155-A827AED8-C812-46A1-8F08-CF0E13A7E71B

Q34607155-AEDADE06-96C3-4F96-9399-0930C21858D4

Q34607155-B9B7B81E-7467-49F9-9958-1ABB7F27754F

P2860

Q34607155-504F008E-9512-420E-8BE2-802A9362B4E1

Q34607155-72942436-F92E-45FE-B6E9-BB82710DF70F

Q34607155-AF22E571-582F-4ED9-B32D-DEB03665874A

Q34607155-CA04B7B2-38A8-4E1D-A956-470AE3FEBE0C

Q34607155-DEF8C47C-7AE6-4264-A82C-6DC859D9B7F8

P304

Q34607155-D51F065F-6C20-4410-850E-B1C30AF2AEF5

P31

Q34607155-B1EF58A2-80C8-45F2-94BF-8BD904245251

P356

Q34607155-81C20539-7018-4FFB-B259-2201662A2F3A

P433

Q34607155-A345C021-0539-40C1-B29D-049908764402

P478

Q34607155-9DDEABBA-6261-4BAD-BFB3-36C8E9B031E7

P50

Q34607155-BA0A3AEA-286B-41D7-8A1F-50C8FBC2B1C0

Q34607155-DC83FF1E-9B3C-4CC1-8F01-A6EB393C3C3E

Q34607155-DF447252-0618-4A0F-989E-D87EC025ED9B

P577

Q34607155-A7E78356-FE19-4182-AC2F-F9AAC9F0DC8B

P5875

Q34607155-29B482D6-AA78-44F4-9D0B-472025588261

P698

Q34607155-514D7D45-904D-4A2C-8EAF-D61CF5F4A8FA

P921

Q34607155-C513E614-B0E2-4D11-96C8-069E3D7199AC

P356

P1433

Inflammatory Bowel Diseases

P1476

Open-label study of adalimumab ...... or intolerance to infliximab.

@en

P2093

Darrell S Pardi

http://www.w3.org/2001/XMLSchema#string

David H Bruining

http://www.w3.org/2001/XMLSchema#string

David T Rubin

http://www.w3.org/2001/XMLSchema#string

Jonathan A Leighton

http://www.w3.org/2001/XMLSchema#string

Karen A Hanson

http://www.w3.org/2001/XMLSchema#string

Russell D Cohen

http://www.w3.org/2001/XMLSchema#string

Stephen B Hanauer

http://www.w3.org/2001/XMLSchema#string

Sunanda V Kane

http://www.w3.org/2001/XMLSchema#string

Waqqas Afif

http://www.w3.org/2001/XMLSchema#string

William A Faubion

http://www.w3.org/2001/XMLSchema#string

P2860

Infliximab for induction and maintenance therapy for ulcerative colitis

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience.

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

P304

1302-1307

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IBD.20924

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Edward V Loftus

William Jeffery Sandborn

William J. Tremaine

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24395191

http://www.w3.org/2001/XMLSchema#string

P698

19408340

http://www.w3.org/2001/XMLSchema#string

P921